Related Experiment Video
Updated: Jul 18, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Antiretroviral therapy for children in the routine setting in Malawi
Insights
Malawi
Area of Science:
- Pediatrics
- Infectious Diseases
- Public Health
Background:
- Malawi is expanding access to antiretroviral therapy (ART) for individuals living with HIV.
- A fixed-dose combination of stavudine, lamivudine, and nevirapine (Triomune) is utilized as the primary treatment regimen.
- Pediatric dosing involves splitting tablets based on body weight.
Purpose of the Study:
- To evaluate the outcomes of antiretroviral therapy (ART) in children compared to adults in Malawi.
- To assess the effectiveness and safety of a fixed-dose combination regimen in pediatric HIV treatment.
- To inform national programs on the importance of pediatric ART and outcome monitoring.
Main Methods:
- Analysis of a national cohort of HIV-infected patients initiated on ART between July-September 2005 and January-March 2005.
- Inclusion of a subset of 935 children with detailed age and gender distribution.
- Cohort outcomes were assessed at six and twelve months, censored on March 31, 2006.
Main Results:
- A total of 46,702 patients initiated ART, with 5.8% being children under 15.
- Six-month outcomes showed significantly higher survival rates and lower mortality/default rates in children compared to adults.
- Twelve-month outcomes also demonstrated significantly better survival rates for children versus adults.
Conclusions:
- Pediatric antiretroviral therapy (ART) in Malawi demonstrates favorable outcomes compared to adults.
- The study supports increased investment in pediatric HIV treatment programs.
- Continuous monitoring of pediatric ART treatment outcomes is crucial for program improvement.
Abstract:
Malawi is scaling up antiretroviral therapy (ART) for HIV-infected patients. Using a fixed-dose combination of stavudine+lamivudine+nevirapine ('Triomune') as the first-line regimen, split tablets are given to children with doses according to body weight. By March 2006, a total of 46 702 patients had been started on ART, of whom 2718 (5.8%) were children aged <15 years. In a subset of 935 children, comprising 486 boys and 449 girls, 1.5% were aged <1 year, 26% were aged 1-4 years, 39% were aged 5-9 years and 33% were aged 10-14 years. Between July and September 2005, 7905 patients started ART, comprising 7469 adults and 436 children. Six-month cohort outcomes censored on 31 March 2006 showed significantly more children alive and significantly fewer children dead or defaulted compared with adults. Between January and March 2005, 4580 patients started ART, comprising 4347 adults and 233 children. Twelve-month cohort outcomes censored on 31 March 2006 showed significantly more children alive compared with adults. The results of this national study should encourage other programmes to invest in ART for children and particularly to monitor their treatment outcomes.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Respiratory Syncytial Virus Disease
Retroviruses
Antiviral Nucleoside Inhibitors
Drug Dosing: Infants and Children

